FTSE 100 today: UK equities slide further on geopolitical jitters, sterling dips

UK retail sales volumes fell 0.4% month-over-month in February 2026, beating consensus of a 0.7% decline and following a revised +2.0% in January. Markets were softer: FTSE 100 -0.4%, Germany’s DAX -1.3%, CAC 40 -0.8%, and GBP/USD down 0.4% to 1.3281 amid ongoing Middle East tensions. The Bank of England lowered and fixed pricing on its Discount Window Facility to enhance on-demand liquidity. Company moves: AstraZeneca shares +2.8% after tozorakimab met primary endpoints in two Phase III COPD trials, while Harbour Energy shares fell over 5% after BASF sold 80m shares at 273p (a 9% discount).

Analysis

The market's reaction to renewed Middle East shipping activity has likely shifted risk premia rather than fundamentals: shorter-lived flow normalization reduces the probability of a sustained supply shock but raises persistent volatility in freight, insurance and spare tanker capacity that is priced into shipping equities and charter rates for the next 3–6 months. That dynamic favors asset owners with limited incremental opex exposure (tanker owners, storage operators) and penalizes activity-sensitive service providers that face lumpy capex cycles when rates swing.

On the UK macro front, an operationally easier Bank of England discount window reduces acute funding tail-risk and should compress short-term stress premia in gilts and bank funding curves; this is a headwind to volatility-driven trading strategies but a modest tailwind for UK financials over the next quarter. Concurrent retail softness implies a multi-quarter drag on ad monetisation and consumer-facing discretionary margins—expect revenue-per-user and CPI-linked pricing power to be the marginal battleground for adtech and consumer tech names over 2–8 quarters.

Within healthcare and technology, recent clinical and trial developments (and the market repricing that follows) materially change optionality: they accelerate regulatory/HTA milestone timing and increase M&A or licensing takeout probability, compressing implied volatility in the underlying equity but opening clear event-driven windows over 6–18 months. By contrast, ad-driven mobile platforms face near-term demand risk that is already signalled by consumer weakness; data-center/AI infrastructure vendors retain a defensive growth premium, making them logical hedges or longs versus adtech exposure.

Key Decisions for Investors

• Long AZN equity or a limited-cost call spread: buy AZN 6–12 month call spread (buy 1x ~12%–20% OTM, sell 1x ~30%–40% OTM) sized to risk 2–4% of portfolio. Rationale: crystallises upside from re-rated clinical optionality/M&A while capping premium; target +25–40% if regulatory/more positive commercial signals arrive within 6–12 months, downside limited to premium (stop if spread value falls 50%).
• Event-volatility play on data-center exposure (SMCI): buy a 3-month ATM straddle or long-dated call (depending on cost) into the next earnings/capex cadence, sized to risk 1–2% of portfolio. Rationale: insulates from mixed macro while capturing asymmetric upside if enterprise/AI capex beats; target 2:1 payoff if share moves >15% around catalyst, loss limited to premium paid.
• Short consumer ad cyclicality (APP): initiate a 3–6 month tactical short or buy puts on APP, or short APP paired with a long NASDAQ/large-cap tech ETF to isolate ad-demand risk. Rationale: consumer confidence and retail weakness pressures ad spend; risk: macro rebound or repricing of ad dollars – cap position size to 1–2% and set a 10% stop to limit event-driven gamma losses; target ~20% downside in 3 months.
• Hedge GBP/UK equity exposures: use 3-month GBP forwards or buy 3-month GBP puts on material UK equity positions to cap FX translation risk while BoE policy operational tweaks are absorbed. Rationale: cushions earnings volatility from currency moves that can otherwise offset domestic operational gains; cost should be treated as <0.5% annualised carry versus protecting outsized equity moves.